DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award
ID: 353167Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353167
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the FY24 Amyotrophic Lateral Sclerosis (ALS) Therapeutic Idea Award, aimed at supporting innovative research for ALS therapy development. This grant opportunity encourages high-risk, high-gain projects that focus on drug or therapy discovery for ALS, requiring a well-formulated hypothesis and consideration of biomarker development for future clinical trials. With an estimated total program funding of $9.8 million available for approximately ten awards, each grant may not exceed $600,000 over a two-year period. Interested applicants must submit a Pre-Application via the Electronic Biomedical Research Application Portal (eBRAP) and a Full Application through Grants.gov by July 10, 2024, with funding decisions expected shortly after the peer review process. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    HT942524ALSRPTIA_GG2.pdf
    The DOD FY24 Amyotrophic Lateral Sclerosis (ALS) Therapeutic Idea Award, part of the Congressionally Directed Medical Research Programs, is open for applications aimed at innovative research for ALS therapy development. The total funding allocated for FY24 is $40 million, with approximately $9.8 million expected for around ten awards, each not exceeding $600,000 over a two-year period. Eligible applicants include organizations from various sectors, including academic and commercial entities, with an emphasis on proposals that demonstrate innovative, high-risk, high-gain therapeutic ideas. Applicants must submit a two-step application process involving a Pre-Application via the Electronic Biomedical Research Application Portal (eBRAP) and a Full Application through Grants.gov. The peer and programmatic review process will evaluate submissions based on innovation, impact, research strategy, and feasibility, alongside biomarker and data sharing considerations. Additionally, projects emphasizing women's health and clearly defined next steps for therapeutic application will be prioritized. The program underscores the necessity for rigorous study design standards and ethical compliance in research involving human and animal subjects, with a clear focus on advancing ALS therapeutics and the development of effective biomarkers. All submissions are due by July 10, 2024, with funding decisions expected shortly after peer reviews are completed.
    HT942524ALSRPTIA.pdf
    Similar Opportunities
    Studies Addressing Rare Neurodegenerative Diseases including ALS
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for studies addressing rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This grant aims to support research that advances the development of medical products intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in both adults and children. The initiative is crucial for addressing significant knowledge gaps in the field and is expected to have a substantial impact on the development of interventions for these conditions. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610 for further information. The FDA anticipates awarding approximately 10 grants in fiscal year 2025, with no cost-sharing or matching requirements.
    Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is inviting research proposals through a cooperative agreement to identify and evaluate potential risk factors for Amyotrophic Lateral Sclerosis (ALS). The opportunity encourages studies focusing on various aspects such as military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents, with four distinct funding options available to support both established and exploratory research. This initiative aims to enhance understanding of ALS risk factors, particularly in affected populations, and to analyze biological samples related to the Guamanian ALS cluster. Interested applicants can reach out to Dr. Candis Hunter at ncipcerpo@cdc.gov or by phone at 770-488-1347. The total estimated funding for this program is $7.5 million, with individual awards ranging from $0 to $500,000, and proposals are due by December 1, 2025, with awards expected to be announced by August 28, 2026.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at investigating novel therapeutic interventions and testing strategies for neurological disorders, specifically targeting the treatment, modification, and prevention of epilepsy. This initiative encourages applicants to explore various intervention modalities and develop human-focused testing approaches, with a particular emphasis on preclinical therapy testing and model development. The total estimated program funding is $6.2 million, with individual awards ranging from $3.5 million to $4 million, and the application process is expected to open with a synopsis posted by December 19, 2025, closing on February 20, 2026. Interested applicants can reach out to Dr. Brian Klein at brian.klein@nih.gov or (301) 496-0981 for further information.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    Department of Defense HIV/AIDS Prevention Program
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research and Materiel Command (USAMRAA), is offering a federal grant opportunity titled the Department of Defense HIV/AIDS Prevention Program (DHAPP). This program aims to save lives and prevent HIV infections by supporting the development of interventions and programs within military health systems, particularly in foreign countries, to achieve HIV/AIDS epidemic control. The DHAPP focuses on enhancing military capacity for ownership and behavioral change, aligning with national strategies, and ensuring sustainable HIV prevention and treatment services. Interested applicants can reach out to Ebony Simmons at ebony.s.simmons.civ@health.mil or by phone at 301-619-2105 for further information. The application deadline is September 18, 2027, with an expected seven awards to be made under this cooperative agreement, which does not require cost sharing or matching.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.